YGION Biomedical GmbH, a company specializing in personalized neoantigen-based cancer vaccines, has successfully completed a Series A financing round, securing €15 million from an Austrian private trust. The funds will be used to further develop YGION's unique YGNITETM technology platform and advance the lead program YG-01 into preclinical and clinical development stages.

Founded in 2022, YGION comprises a team of experienced biotech professionals and entrepreneurs committed to developing individualized cancer vaccines. Through proprietary technologies, the company aims to identify, produce, and target the delivery of relevant peptide neoepitopes, activating the patient's immune system safely and effectively.

YGION, stated, "We are on the verge of a breakthrough in individualized cancer treatments. This financing is a strong validation of our approach, and we are grateful for the support of our investors. With the continued efficacy of our approach, we welcome additional investors and collaborators interested in our ground-breaking approach."

YGION, emphasized, "Our technology can deliver simple, safe, and effective cancer vaccines. The YGNITETM platform allows us to identify, select, and synthesize relevant neoantigens, combined with our CARGONAUTTM immune-modulating carrier, inducing a powerful response that targets and eliminates malignant cells with unmatched safety."

YGION's lead program YG-01 is currently undergoing preclinical development.

 

Source: prnewswire.com

Report Abuse